A detailed history of Armstrong Advisory Group, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Armstrong Advisory Group, Inc holds 56 shares of VRTX stock, worth $25,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56
Previous 97 42.27%
Holding current value
$25,220
Previous $45,000 42.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$460.0 - $505.78 $18,860 - $20,736
-41 Reduced 42.27%
56 $26,000
Q2 2024

Jul 12, 2024

BUY
$392.81 - $485.53 $18,854 - $23,305
48 Added 97.96%
97 $45,000
Q2 2023

Jul 06, 2023

SELL
$314.42 - $351.91 $52,193 - $58,417
-166 Reduced 77.21%
49 $17,000
Q1 2023

Apr 07, 2023

BUY
$283.23 - $323.1 $13,878 - $15,831
49 Added 29.52%
215 $67,000
Q4 2022

Jan 17, 2023

BUY
$285.76 - $321.48 $47,436 - $53,365
166 New
166 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Armstrong Advisory Group, Inc Portfolio

Follow Armstrong Advisory Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armstrong Advisory Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Armstrong Advisory Group, Inc with notifications on news.